Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

CJC-1295 No DAC & Ipamorelin: Research Application Comparison

CJC-1295 No DAC GHRH receptor agonist ~30 minutes Increases GH pulse amplitude High (targets GHRH receptors specifically) 100–200 mcg per dose Amplifying endogenous GH secretory events without sustained elevation Ipamorelin Ghrelin receptor agonist (GHSR-1a) ~

This comparison does not assign a generated winner or score.

  • CJC-1295 No DAC
  • GHRH receptor agonist
  • ~30 minutes
  • Increases GH pulse amplitude
  • High (targets GHRH receptors specifically)
  • 100–200 mcg per dose
  • Amplifying endogenous GH secretory events without sustained elevation
  • Ipamorelin
  • Ghrelin receptor agonist (GHSR-1a)
  • ~2 hours
  • Increases GH pulse frequency and amplitude
  • Very high (minimal cortisol/prolactin effect)
  • 200–300 mcg per dose
  • Selective GH stimulation without metabolic side effects seen in older secretagogues
  • Combined Protocol
  • Dual receptor activation (GHRH + ghrelin pathways)
  • Pulsatile (peaks at 20–30 min)
  • Synergistic GH release (2–3× single peptide effect)
  • Maintained (both peptides are selective)
  • 100–200 mcg CJC / 200–300 mcg Ipa
  • Body recomposition research requiring maximal GH stimulation with minimal off-target hormonal disruption
  • CJC-1295 With DAC
  • GHRH receptor agonist (extended-release)
  • 6–8 days
  • Sustained GH elevation
  • High
  • 2 mg weekly (single dose)
  • Protocols prioritising convenience over pulsatile rhythm. Produces blunted but prolonged GH increase
  • GHRP-6
  • Ghrelin receptor agonist (non-selective)
  • GH release + cortisol + prolactin elevation
  • Low (broad receptor activation)
  • Early secretagogue research. Now largely replaced by Ipamorelin due to side effect profile
  • Professional Assessment
  • CJC-1295 no DAC + Ipamorelin is the current gold standard for fat loss and body recomposition research. The combination produces the highest GH pulse amplitude with the fewest off-target hormonal effects. Older peptides like GHRP-6 or extended-release CJC with DAC are superseded by this protocol in almost every research context.
More references

Related material